RU2020124276A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020124276A3 RU2020124276A3 RU2020124276A RU2020124276A RU2020124276A3 RU 2020124276 A3 RU2020124276 A3 RU 2020124276A3 RU 2020124276 A RU2020124276 A RU 2020124276A RU 2020124276 A RU2020124276 A RU 2020124276A RU 2020124276 A3 RU2020124276 A3 RU 2020124276A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243381P | 2015-10-19 | 2015-10-19 | |
| US62/243,381 | 2015-10-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018118177A Division RU2728710C2 (ru) | 2015-10-19 | 2016-10-14 | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020124276A RU2020124276A (ru) | 2021-08-03 |
| RU2020124276A3 true RU2020124276A3 (https=) | 2022-01-18 |
Family
ID=57223732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018118177A RU2728710C2 (ru) | 2015-10-19 | 2016-10-14 | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
| RU2020124276A RU2020124276A (ru) | 2015-10-19 | 2016-10-14 | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018118177A RU2728710C2 (ru) | 2015-10-19 | 2016-10-14 | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190330328A1 (https=) |
| EP (1) | EP3365011A1 (https=) |
| JP (4) | JP6858766B2 (https=) |
| KR (1) | KR20180064415A (https=) |
| CN (1) | CN108367074A (https=) |
| AU (4) | AU2016342578A1 (https=) |
| CA (1) | CA3002622A1 (https=) |
| HK (1) | HK1251481A1 (https=) |
| IL (2) | IL257723B2 (https=) |
| RU (2) | RU2728710C2 (https=) |
| WO (1) | WO2017068472A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103154031A (zh) | 2010-10-08 | 2013-06-12 | 诺华有限公司 | 利用il-17拮抗剂治疗牛皮癣的方法 |
| BR112013011176A2 (pt) | 2010-11-05 | 2020-09-01 | Novartis Ag | métodos de tratamento de artrite reumatoide usando antagonistas de il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CA3002622A1 (en) * | 2015-10-19 | 2017-04-27 | Novartis Ag | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
| CN116059350A (zh) | 2015-10-27 | 2023-05-05 | Ucb生物制药有限责任公司 | 使用抗-il-17a/f抗体的治疗方法 |
| US11299540B2 (en) | 2017-06-18 | 2022-04-12 | Kindred Biosciences, Inc. | IL17A antibodies and antagonists for veterinary use |
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| EP4591879A3 (en) | 2019-01-31 | 2025-10-22 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| EP3963541A1 (en) * | 2019-04-29 | 2022-03-09 | UCB Biopharma SRL | Medical image analysis system and method for identification of lesions |
| TW202126329A (zh) * | 2019-09-20 | 2021-07-16 | 瑞士商諾華公司 | 使用白細胞介素－１７（ｉｌ－１７）拮抗劑治療自體免疫性疾病之方法 |
| US20240012009A1 (en) * | 2020-11-05 | 2024-01-11 | Keyintel Medical Inc. | Methods for systematically assessing local inflammation and active repair |
| EP4471427A1 (en) * | 2023-05-31 | 2024-12-04 | Centre Hospitalier Universitaire De Nice | Biomarker for spondyloarthitis diagnostic and response to treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| BRPI0706788A2 (pt) | 2006-01-31 | 2011-04-05 | Novartis Ag | anticorpos antagonistas il-17 |
| BR112013011176A2 (pt) * | 2010-11-05 | 2020-09-01 | Novartis Ag | métodos de tratamento de artrite reumatoide usando antagonistas de il-17 |
| WO2013158821A2 (en) * | 2012-04-20 | 2013-10-24 | Novartis Ag | Methods of treating ankylosing spondylitis using il-17 antagonists |
| CA3002622A1 (en) * | 2015-10-19 | 2017-04-27 | Novartis Ag | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
-
2016
- 2016-10-14 CA CA3002622A patent/CA3002622A1/en active Pending
- 2016-10-14 JP JP2018519903A patent/JP6858766B2/ja active Active
- 2016-10-14 CN CN201680072561.XA patent/CN108367074A/zh active Pending
- 2016-10-14 WO PCT/IB2016/056166 patent/WO2017068472A1/en not_active Ceased
- 2016-10-14 IL IL257723A patent/IL257723B2/en unknown
- 2016-10-14 RU RU2018118177A patent/RU2728710C2/ru active
- 2016-10-14 EP EP16790436.6A patent/EP3365011A1/en active Pending
- 2016-10-14 IL IL297775A patent/IL297775A/en unknown
- 2016-10-14 HK HK18111096.0A patent/HK1251481A1/zh unknown
- 2016-10-14 RU RU2020124276A patent/RU2020124276A/ru unknown
- 2016-10-14 AU AU2016342578A patent/AU2016342578A1/en not_active Abandoned
- 2016-10-14 US US15/766,043 patent/US20190330328A1/en not_active Abandoned
- 2016-10-14 KR KR1020187010627A patent/KR20180064415A/ko not_active Ceased
-
2019
- 2019-09-30 AU AU2019240551A patent/AU2019240551A1/en not_active Abandoned
-
2021
- 2021-03-23 JP JP2021048873A patent/JP7389077B2/ja active Active
- 2021-10-01 AU AU2021240290A patent/AU2021240290A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023116721A patent/JP2023134701A/ja not_active Withdrawn
-
2024
- 2024-04-05 US US18/628,097 patent/US20250066466A1/en active Pending
- 2024-12-04 AU AU2024278118A patent/AU2024278118A1/en active Pending
-
2025
- 2025-10-06 JP JP2025168405A patent/JP2026010006A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180064415A (ko) | 2018-06-14 |
| HK1251481A1 (zh) | 2019-02-01 |
| US20250066466A1 (en) | 2025-02-27 |
| JP7389077B2 (ja) | 2023-11-29 |
| CN108367074A (zh) | 2018-08-03 |
| AU2016342578A1 (en) | 2018-03-29 |
| IL257723B2 (en) | 2023-04-01 |
| IL257723B (en) | 2022-12-01 |
| JP2021100956A (ja) | 2021-07-08 |
| AU2021240290A1 (en) | 2021-11-11 |
| AU2024278118A1 (en) | 2025-01-02 |
| JP6858766B2 (ja) | 2021-04-14 |
| RU2018118177A3 (https=) | 2020-02-17 |
| RU2018118177A (ru) | 2019-11-21 |
| US20190330328A1 (en) | 2019-10-31 |
| IL257723A (en) | 2018-04-30 |
| JP2023134701A (ja) | 2023-09-27 |
| JP2026010006A (ja) | 2026-01-21 |
| CA3002622A1 (en) | 2017-04-27 |
| JP2018537418A (ja) | 2018-12-20 |
| AU2019240551A1 (en) | 2019-10-17 |
| EP3365011A1 (en) | 2018-08-29 |
| RU2020124276A (ru) | 2021-08-03 |
| IL297775A (en) | 2022-12-01 |
| WO2017068472A1 (en) | 2017-04-27 |
| RU2728710C2 (ru) | 2020-07-30 |